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Characterization of a recurrent
missense mutation in the forkhead
DNA-binding domain of FOXP1
Tyler B. Johnson 1, Keegan Mechels1, Ruth Ellen Anderson1, Jacob T. Cain 1,
David A. Sturdevant1, Stephen Braddock3, Hailey Pinz3, Mark A. Wilson4, Megan Landsverk2,
Kyle J. Roux1,2 & Jill M. Weimer1,2
Haploinsufficiency of Forkhead box protein P1 (FOXP1), a highly conserved transcription factor, leads to
developmental delay, intellectual disability, autism spectrum disorder, speech delay, and dysmorphic
features. Most of the reported FOXP1 mutations occur on the C-terminus of the protein and cluster
around to the forkhead domain. All reported FOXP1 pathogenic variants result in abnormal cellular
localization and loss of transcriptional repression activity of the protein product. Here we present three
patients with the same FOXP1 mutation, c.1574G>A (p.R525Q), that results in the characteristic loss of
transcription repression activity. This mutation, however, represents the first reported FOXP1 mutation
that does not result in cytoplasmic or nuclear aggregation of the protein but maintains normal nuclear
localization.
Haploinsufficiency of forkhead box protein P1 (FOXP1) causes a rare neurodevelopmental disorder that is characterized by a vast array of symptoms that include developmental delay, motor coordination deficits, specific language impairment, autistic features, intellectual disabilities, dysmorphic features, various cancers, and congenital
defects of the heart, kidneys and urinary tract1,2 (MIM 605515 (gene); MIM 613670 (disorder)). The FOX proteins
are a family of evolutionarily conserved transcription factors that share a characteristic winged-helix (forkhead)
DNA-binding domain. Members of the FOXP subfamily, which includes four paralogous proteins, have crucial
roles in embryonic development and organogenesis of heart, lung, esophagus, and immune system3–8. Each of
these proteins share four common domains: an N-terminal Q-rich (polyglutamine) domain, internal zinc-finger
and leucine zipper, and a C-terminal forkhead box DNA-binding domain (FOX).
FOXP1 is widely expressed in human and mouse tissues with specific regional expression in the central nervous system including the cerebral cortex, striatum, and spinal cord6,9–11. Its role is crucial in these regions during
cortical development for regulation of neuronal migration, differentiation, and morphogenesis8,12,13. Suppression
of Foxp1 within the developing brain leads to radial migration defects where neurons improperly localize, as
well as problems with morphogenesis and neurite outgrowth8. Foxp1 binds a 7-nucleotide consensus sequence,
TATTT(G/A)T, and represses transcription at target locations, including SV40 and interleukin-2 promoters14,
and directly regulates expression of genes important for neurogenesis12. FOXP1 also directly binds to and controls expression of genes associated with autism9 and abnormalities of the central nervous system, musculature,
cognition, and higher mental function12. Proteomic studies also show that FOXP proteins directly interact with
partners with diverse roles in neurodevelopment including migration of cortical projection neurons, cortical
neuron plasticity, and neurogenesis15.
Outside the CNS, FOXP1 plays an important role in development monocytes and macrophages16, regulatory T-cells17, cardiomyocytes7, lung epithelial cells18. In immune cells, overexpression of FOXP1 in mouse
monocytes impaired monocyte differentiation, migration and macrophage function through repression of
colony-stimulating factor receptor16. Additionally, deletion of Foxp1 in mice influences B-cell and thymocyte
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Figure 1. FOXP1 p.R525 mutations map to the FOX DNA-binding domain. FOXP1 protein structure is
composed of common conserved domains: an N-terminal Q-rich (polyglutamine) domain, internal zinc-finger
(ZF) and leucine zipper (LZ), and a C-terminal forkhead box DNA-binding domain (FOX). Additionally, two
nuclear localization signals (NLS) are present at the C-terminus that target the protein to the nucleus under
normal conditions. Arginine 525 is localized to the DNA-binding FOX domain nestled between the two NLS.

development3,19. Foxp1 also plays an important role in cardiac development as Foxp1 null mice are embryonic
lethal due to defects in myocyte maturation leading to thinning of the ventricular myocardial compact zone7.
The native FOXP1 sequence encodes conserved functional domains that dictate its cellular functions (Fig. 1).
The N-terminus of the protein contains a polyglutamine (Q-rich) domain, putative zinc finger and leucine zipper
domains. Q-rich domains, which are sequences that are commonly present in many transcription factors20, have
been demonstrated to be important for protein-protein interactions21 as well as modulation of transcriptional
repression activity14,22. Additionally, the zinc finger and leucine zipper contribute to protein-protein interactions
and transcriptional repression, as is the case for many other proteins containing these domains14,23–26. Through
the leucine zipper domain, FOXP1 is able to form specific homo- and heterodimers with its paralog FOXP227.
Near the C-terminus are two nuclear localization sequences resulting in the protein’s natural localization to the
nucleus in normal tissues and cells2,28,29 and a forkhead box DNA-binding domain (FOX); however, exogenously
expressed pathogenic variants result in disrupted nuclear localization and formation of cytoplasmic and nuclear
aggregates27,29–31. Additionally, these mutations result in loss of both transcriptional repression activity and typically the ability to form dimers with wild type FOXP1 and FOXP229,31,32, although there are reported variants that
preserve their dimerization capability29.
The C-terminal FOX domain, which is critical for its activity as a transcriptional repressor, is the site of more
than 80% of all pathogenic missense mutations. The FOX domain is composed of 88 amino acids that are organized into five α-helices and three β-sheets some of which are directly involved in recognition and binding to
DNA as well as protein-protein interactions through domain swapping33. Siper et al. provided a comprehensive
discussion on the structural consequences of missense and in-frame mutations occurring in the FOX domain
that have been identified in patients2. Notably, these mutations all occur on residues important for DNA-binding
or protein-protein dimerization. They discuss the implications of changes in amino acid sequence in the FOX
domain and note possible obstruction of electrostatic interactions with DNA, DNA recognition, and aberrant
protein folding and dimerization.
Several studies have reported a wide spectrum of de novo human mutations in FOXP1 including deletions34–38,
nonsense and missense variants1,29,39,40, frameshifts30, and translocations41. Here, we present three patients with a
missense c.1574G>A (p.R525Q) mutation at the same residue. Although the clinical presentation of patient one
has been described in detail1,39, the effect of this alteration on FOXP1 localization and activity has never been
demonstrated. We provide biochemical characterization of the localization of the protein and a measure of its
transcriptional repression activity. Finally, this represents the first reported case of a FOXP1 missense mutation
with normal nuclear localization and aberrant transcriptional repression.

Results

Clinical assessment. The first patient reported to have a de novo c.1574G>A (p.R525Q) mutation in FOXP1

was previously described in two separate reports1,39. Briefly, the patient was born to a non-consanguineous couple
of Northern European ancestry and had respiratory distress and a left pneumomediastinum shortly after birth.
By the age of four, he had presented with horseshoe kidney, hypospadias, urinary tract defects, recurrent fevers,
dysmorphic features, global developmental delays, speech delay and autism. He also had undertubulation and
shortening of the long bones of the upper and lower extremities as well as episodes of relapsing-remitting fevers.
Patient two presented to the genetics clinic as an adult with significant intellectual disability including substantial expressive language delay. He had a history of failure to thrive with delayed pubertal development and low
testosterone. The patient was normocephalic with a normal skull shape, a tall, sloped forehead, and arched eyebrows with synophrys. He had a normal chin and ears and palate was intact, his teeth were crowded and irregular.
He was in constant motion with many self-stimulatory behaviors including kicking, biting, and throwing himself
to the ground. He was able to follow directions and carry out tasks but was unable to express himself. An EKG was
normal. Whole exome sequencing in a commercial laboratory on the patient and both of his parents revealed the
same de novo FOXP1 variant, c.1574G>A (p.R525Q).
Patient three was born to non-consanguineous parents of mixed European descent. The pregnancy was complicated by spotting, sub chorionic hemorrhage, elevated maternal serum alpha-fetoprotein (MSAFP), possible Dandy-Walker malformation (DWM) with bilateral ventriculomegaly, unilateral ureteral dilation, and fetal
macrosomia. He was delivered vaginally at 34 3/7 weeks without complication. The birth weight was 3140 g and
length was 46 cm. Apgar scores were 8 and 8, at 1 and 5 minutes, respectively. He was admitted to the neonatal
intensive care unit for management of respiratory distress. Hypoglycemia and jaundice were also noted. Postnatal
imaging and examination revealed a horseshoe kidney with right hydronephrosis, bilateral undescended testes,
and mega cisterna magna versus arachnoid cyst, without evidence of DWM. At approximately six months of life,
the patient was diagnosed with sagittal craniosynostosis and macrocephaly. The patient underwent cranial vault
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reconstruction at age nine months. The patient sat unsupported at 12 months, crawled at 14 months, and walked
at 18 months. He was evaluated by child psychology at 1.5 years and was felt to have low average cognition and
borderline expressive/receptive language abilities. The patient presented to the genetics clinic at age 2 years 7
months. He did not have any verbal speech, but did know some signs and communicated with pointing at time
of initial evaluation. Macrocephaly was noted (OFC 53.8 cm, >99th centile) as well as a broad, tall forehead with
a prominent, pointed chin. Ears were well-formed, but low-set. The palate was intact with a mild prominent secondary alveolar ridge and his height was 96 cm (86th percentile). He could run and jump, but was notably clumsy.
At the time of the most recent follow up (age 2 years, 11 months) he could say 7 words, knew 6 signs, and was
working with a picture system. He could follow multi-step commands. At that time, he could also identify people
and colors, and was working to help dress himself. He wore ankle and foot orthoses (AFOs) due to low tone and
unsteady gait, as well as a helmet intermittently for protection from falls, although clumsiness was reportedly
continuing to improve. The family described the patient to have sensory issues and a bad temper with hitting, biting, and throwing objects when not getting his way. He was working on toilet training. Whole exome sequencing
in a commercial laboratory revealed the FOXP1 c.1574G>A (p.R525Q) mutation. A maternal sample was not
available; however, paternal and unaffected full sibling’s samples were negative for the mutation. No additional
variants were identified.

The FOXP1 p.R525Q mutation maintains nuclear localization but loses transcriptional repression. To determine the effect of the missense p.R525Q on cellular localization, we transiently transfected

HeLa cells with constructs overexpressing WT FOXP1, a truncating mutant FOXP1 p.R525*, or the p.R525Q
mutant, all fused to an N-terminal GFP reporter (Fig. 2). We performed immunolabeling for the GFP reporter
and analyzed the cells by laser scanning confocal microscopy. Wild type FOXP1 localizes to the nucleus like most
functional transcription factors (Fig. 3). The truncating mutant (p.R525*) aggregates in the cytoplasm while the
missense mutant (p.R525Q) maintained nucleoplasmic localization similar to wild type FOXP1 (Fig. 3).
Mutations in FOXP1 result in drastic reduction of SV40 promoter repression in vitro29. In order to evaluate
transcriptional repression activity of the missense mutant compared to wild type and p.R525* levels, we tested
the ability of the p.R252Q variant to repress the SV40 promoter. Despite normal nuclear localization of missense
mutant, the ability to transcriptionally repress the SV40 promoter was severely diminished as was the case for the
truncating mutant (Fig. 4).

Discussion

Many cases of de novo mutations in FOXP1 have been reported including full and partial gene deletions34–38, nonsense and missense variants1,29,39,40, frameshifts30, and translocations41. Shared among the patients harboring heterozygous mutations in FOXP1 are conditions including intellectual disability, language impairment, autistic features,
motor coordination and dysmorphic features also occasionally presenting with various cancers, and congenital
defects of the heart, kidneys and urinary tract1,2. In this study, we report three patients with a p.R525Q missense
mutation in the transcriptional repressor FOXP1. These patients all presented with the typical intellectual disability,
autism spectrum disorder, language impairment, and behavioral tendencies including aggressiveness and obsessions. However, some of the additional clinical features noted in our patients such as the skeletal anomalies and
fevers in patient one and the macrosomia in patient three have not been previously reported in patients with FOXP1
mutations. The cause of neonatal macrosomia is unknown. Prenatal work ruled out maternal diabetes and there
were no other variants identified on whole exome sequencing. The patient did have an 11q14.1 deletion on chromosomal microarray analysis, an intronic deletion of DLG2 that has been identified in one normal control, which
was considered to be a variant of unknown significance. Ultimately, we felt the deletion to be noncontributory, and
there is certainly no evidence to link it to his history of neonatal macrosomia. Whether the additional features in
these patients are a result of the FOXP1 mutation alone or additional unidentified genetic alterations is yet unclear.
Forkhead box proteins are a highly conserved class of transcription factors with a diverse role in development
and disease. An inherent characteristic of most transcription factors is that they maintain their presence in the
nucleus in order to activate or repress the transcription of genes in response to certain stimuli. FOXP1 localization
is no exception to this rule, adhering to nuclear localization under normal circumstances28. To date, 41 different
mutations have been reported in the FOXP1 gene (Summary in2). The Arg525 amino acid appears to be a mutational hotspot as, to date, five additional patients have been reported harboring a p.R525* mutation2,32,42. Sollis et
al. determined that regardless of the mutation, FOXP1 mutants lost transcriptional repression activity and always
resulted in cytoplasmic and/or nuclear aggregation of the resulting protein product, likely due to protein misfolding and loss of NLS sequences or functional loss of NLS motifs29. These mutations do not affect the NLS primary
sequence but must structurally destabilize the domain sufficiently to impair NLS functionality. Here, the p.R525Q
mutant construct, which is predicted to do no more than impair DNA binding, displayed normal nuclear localization. However, we show that the mutation resulted in severely diminished transcriptional repression indicating
that DNA-binding was affected by the amino acid substitution while NLS activity is retained.
The amino acid sequence of the forkhead DNA binding domain of human FOXP1 is 87% identical to the corresponding domain of FOXP2, and thus the structures of these proteins are likely to be highly similar. The 1.9 Å
resolution X-ray crystal structure of human FOXP2 in complex with DNA (PDB 2A0743) thus provides a useful
model for understanding the likely impact of the R525Q mutation in FOXP1. Arg564 of FOXP2 (corresponding to FOXP1 Arg525) makes multiple stabilizing contacts with DNA and other protein elements. The cationic
sidechain of Arg564 makes favorable electrostatic interactions with both a backbone phosphate of the target DNA
and Glu566. Glu566 is conserved in FOXP1, where it is Glu527 (Fig. 5). We predict that a R525K mutation, which
preserves charge, would at least partially rescue the phenotype. However, the guanidinium group of Arg positions
three H-bond donors about ~2.3 Å apart, which is ideal for making multiple H-bonds with anionic acceptors such
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Figure 2. Expression of FOXP1 transcripts in HeLa cells. Expression constructs containing wild type (WT)
FOXP1, p.R525* truncating mutant (RX), p.R525Q missense mutant (RQ) or GFP-only control were transiently
transfected into HeLa cells. (a,b) The WT and RQ mutant produce full-length protein while the truncating
mutant results in a loss of 152 amino acids at the C-terminus of the protein and a band near 75 kDa. Equal mass
was loaded in each lane and (c) beta-actin was used as loading control. Blots are cropped to show bands of
interest. Full-length blots are presented in Supplementary Figure 1.

as carboxylate side chains or phosphates. The structure of Foxp2 shows that R564 makes multiple H-bonds that
include the phosphate backbone, a proximal Glu, and an ordered water. Lysine is a more limited H-bond donor,
and a Lys at this position could not satisfy all of these H-bond acceptors simultaneously. Therefore, we expect that
the R525K phenotype would be intermediate between the R525Q and wild-type ones. Although this Arg residue
is within ~10 Å of the dimer interface in PDB 2A07, it does not make any dimer-spanning contacts. It is difficult
to strictly rule out dimer destabilization without experimentally assessing this, but the structure of the homologous FOXP2 indicates that dimer disruption is not likely to be the primary effect of the R->Q substitution at this
location. Additionally, we cannot exclude alteration in any known FOXP1 protein binding partners as the only
structures available for analysis are DNA-bound FoxP2, not complexes with other proteins. Within the limits of
what is available for us to analyze, the R525 environment is dominated by DNA-protein and intrachain protein
contacts that would make protein-protein contacts less likely without a major conformational change. Therefore,
the clinical p.R525Q mutation in FOXP1 likely destabilizes both intra-protein and protein-DNA interactions due
to loss of the cationic guanidinium sidechain of Arg525.
In summary, we have shown that three patients with the same missense mutation (p.R525Q) in the forkhead
box DNA-binding domain of FOXP1 results in global developmental delay, autism spectrum disorder, and characteristic dysmorphic features. Although other variant FOXP1 mutations result in the same clinical presentation
resulting from loss of transcriptional repression activity and protein aggregation, the p.R525Q mutation maintains normal nuclear localization as the mutation is predicted to only disrupt protein-DNA complexes rather than
its NLS signals. Thus, small changes in the DNA-binding domain of FOXP1 that alter electrostatic interactions
with DNA and proteins appear to severely affect its function despite translation of full-length protein. Future
work comparing cellular transcriptomes of p.R525Q, p.R525*, and other FOXP1 variants would identify some
of the shared fundamental changes among these mutations that lead to a similar clinical phenotype in patients.
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Figure 3. Localization of the FOXP1 proteins in HeLa cells. Expression constructs containing WT FOXP1,
truncating p.R525* mutant, and p.R525Q missense mutant were transiently transfected into HeLa cells. WT
and p.R525Q mutant properly localize to the nucleus in identical patterns while the p.R525* truncation results
in cytoplasmic aggregation.

Figure 4. Luciferase activity resulting from transcriptional repression of the SV40 promoter. The bars represent
the relative transcriptional activity of the SV40 promoter resulting from co-transfection with plasmids
containing the FOXP1 nonsense mutants. The results are mean values ± SEM of experiments performed in
technical triplicate. RX and RQ variants result in severely diminished transcriptional repression of the SV40
promoter as compared to WT levels.

Methods

Plasmid generation. FOXP1 genes were amplified from human cDNA (HsCD00297105, ORFeome
Collaboration, Harvard PlasmID Database) and inserted into pcDNA3.1 (Addgene, Cat. No. #) for
N-terminal fusion with GFP by In-Fusion cloning (Clontech). The GFP pcDNA3.1 was linearized by digestion with XhoI and AflII. Primers pairs designed to contain a 15 bp homologous region to the flanking
sequences of pcDNA3.1 included 5′-GACGAGCTGTACAAGGACCTCGAGATGCAAGAATCTGGG-3′
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Figure 5. Residue R525 of human FOXP1 is predicted to interact with both DNA and nearby residues. (A)
Chain K of the forkhead domain of human FOXP2 (PDB 2A07) bound to DNA43. DNA is depicted in balland-stick and FoxP2 is shown as a ribbon diagram with α-helices colored orange and β-strands colored blue.
The forkhead domain of FoxP2 shares 87% sequence identity with human FoxP1. Residue R564 in FOXP2
(corresponding to R525 in FOXP1) is located at the protein-DNA interface. The red circle shows the area that is
depicted in panel B. (B) A closer view of the environment of R564 (R525 in human FOXP1). Residue numbers
in PDB 2A07 are indicated; their corresponding human FOXP1 numbering shown in parentheses. Potential
hydrogen bonding interactions are shown in dotted lines with distances indicated in Ångstroms. “Wat” indicates
an ordered water molecule mediating H-bonds between protein and DNA. R525 in human FOXP1 is likely to
make similar contacts, which the R525Q mutation likely disrupts. Figure made with POVScript+47.
& 5′-GATCAGCGGTTTAAACTTAAGCTACTCCATGTCCTCGTT-3′ used to amplify the FOXP1 WT
insert; and 5′-GACGAGCTGTACAAGGACCTCGAGATGCAAGAATCTGGG-3′ & 5′-GATCAGCG
GTTTAAACTTAAGTCACACAAAACACTTGTG-3′ used for the p.R525X truncating mutation
insert. A three-piece In-fusion cloning strategy was used to generate the p.R525Q plasmid with primers spanning the missense mutation (underlined) as follows 5′ GACGAGCTGTACAAGGACCTCGAGAT
GCAAGAATCTGGG-3′ & 5′-TTAACGTTTTCTACTTGC ACAAAACACTTG-3′; and subsequently
5′-CAAGTGTTTTGTGCAAGTAGAAAACGTTAA-3′& 5′-GATCAGCGGTTTAAACTTAAGCTAC
TCCATGTCCTCGTT-3′ to generate products of 472 and 1586 bps respectively. The insert to vector molar ratio
for HD recombination was approximately 3:1 or 2:2:1. All PCR reactions used CloneAmp HiFi PCR Premix
(Takara Bio USA, Cat. No. 639298) as per manufacturer’s recommendations with an annealing temperature of
70 °C. Insertion of gene sequences was confirmed by Sanger sequencing.

Western blot.

Cell Lysates were collected in 200 ul of Laemmli Buffer (BioRad), heated to 98 C for five minutes, and sonicated. 10 ul of lysate was ran on precast gradient gels, 4–20%, and then transferred to a nitrocellulose membrane using the BioRad Turbo Transfer System. Primary antibody incubation was performed with
rabbit anti-FOXP1 (Abcam; ab1664544) or chicken anti-GFP antbodies (Abcam; ab1397045), followed by a secondary antibody incubation using goat anti-rabbit HRP and goat anti-chicken HRP antibodies (Santa Cruz),
respectively. Bands were then visualized with Luminata Forte Western HRP substrate (Millipore) and imaged
using UVP-gel documentation system.
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Immunocytochemistry. Transient transfections were carried out as previously described46. Briefly, HeLa
cells were grown in 24 well plates on coverglass to 60–80% confluency. Cells were transfected with 500 ng pcDNA
3.1_FoxP1 WT, p.R525*, or p.R525Q separately using Lipofectamine 3000 reagents (Thermo Fisher Scientific)
following the manufacturer’s suggested protocol. After 48 hours, cells were fixed with 3% paraformaldehyde for
20 minutes. Primary antibody incubation was performed with rabbit anti-FOXP1 (Abcam) and chicken anti-GFP
antibodies (Abcam) followed by a secondary antibody incubation using anti-rabbit-568, anti-chicken-488
(Invitrogen), and DAPI (Life Technologies). Imaging for cellular localization was carried out on a Nikon Ni-E
microscope equipped with a Photometrics CoolSNAP Myo camera. Exposures for each channel were 700 ms
(DAPI), 900 ms (GFP), and 300 ms (Texas Red).
Luciferase assay. HEK 293 cells were grown in DMEM (Corning) supplemented with 10% Fetal Bovine
Serum (VWR) and 1% Penicillin/Streptomycin (HyClone) in 24 well plates. When the cells reached 80% confluence, co-transfection of pcDNA3.1-FOXP1 (250 ng), DBH-pGL3-basic (250 ng), and pRL-TK (25 ng, Promega)
was done using Lipofectamine 2000 (ThermoFisher) following the manufacturer’s suggested protocol. After
24 hours, fresh DMEM was added and 24 hours later the cells were lysed using 1X Passive lysis buffer (Promega).
Firefly and Renilla luciferase activity was detected using the Dual-Luciferase Reporter Assay System (Promega)
following the manufacturer’s suggested protocol. Luciferase activity readings were acquired on biological triplicates and technical triplicates using a Promega GlowMax 96 well luminometer (Promega). 1-way ANOVA with
Fisher’s LSD test were used for statistical analysis.

Data Availability

The datasets generated during and/or analysed during the current study are available from the corresponding
authors on reasonable request.
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